Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001785530-25-000031
Filing Date
2025-11-04
Accepted
2025-11-04 07:11:00
Documents
66
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q howl-20250930.htm   iXBRL 10-Q 1527949
2 EX-10.1 a09302025ex101.htm EX-10.1 9464
3 EX-31.1 a09302025ex311.htm EX-31.1 10203
4 EX-31.2 a09302025ex312.htm EX-31.2 10227
5 EX-32.1 a09302025ex321.htm EX-32.1 6958
  Complete submission text file 0001785530-25-000031.txt   6261351

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20250930.xsd EX-101.SCH 37057
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT howl-20250930_cal.xml EX-101.CAL 60262
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT howl-20250930_def.xml EX-101.DEF 189104
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20250930_lab.xml EX-101.LAB 529514
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20250930_pre.xml EX-101.PRE 382895
69 EXTRACTED XBRL INSTANCE DOCUMENT howl-20250930_htm.xml XML 681239
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40366 | Film No.: 251446428
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)